lunes, 2 de octubre de 2023

Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial

https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00372-3/fulltext?dgcid=hubspot_email_covidalerts&utm_campaign=covidalerts&utm_medium=email&_hsmi=276355044&_hsenc=p2ANqtz-8w6d61M_uBX_VuTRZRXpcMgJUDLiIEMlxyifF28UbPxSInulCum0bJ9OfDddbv38RsFClkptpc9rLv8r-5w-3iqFxE_w&utm_content=276317812&utm_source=hs_email

No hay comentarios:

Publicar un comentario